For informational purposes only. Not financial advice, not a recommendation to buy or sell any security. Standing Order is a directory and research project, not an advisory service.
Price · 1Y
$195.00
Thesis
Moderna is a pure-play mRNA platform company. The COVID franchise that funded the build-out is running off, and the equity case now depends on translating the platform into a durable pipeline — RSV, flu combinations, personalized cancer vaccines with Merck, and rare-disease programs.
The platform thesis is real, but cash burn against a shrinking COVID base means the next two years are about pipeline readouts and disciplined cost control rather than top-line growth.
Catalysts
- Personalized cancer vaccine (INT) phase 3 progress with Merck
- Flu and COVID-flu combination approvals and uptake
- Rare-disease readouts validating the broader platform
- Operating-cost reductions stabilizing the cash runway
Recent events
Material filings, federal awards, and regulatory activity. Impact is scored against market cap.
- Nov 16DealSEC
8-K filed with items 1.01 and 2.03 covering entry into material definitive agreement and creation of direct financial obligation.
- Nov 13LeadershipSEC
8-K reports item 5.02 officer or director change with exhibits.
- Nov 6Financial resultsSEC
Moderna files 8-K (items 2.02, 9.01) disclosing results of operations and financial condition.
- Sep 30LeadershipSEC
8-K filing (items 5.02, 7.01, 9.01) disclosing officer departure or appointment and related exhibits.
- Sep 1OtherSEC
Moderna 8-K filed with items 1.01, 2.03, 3.02, 8.01, 9.01 covering material agreements and equity securities.
- Jul 31Financial resultsSEC
Moderna files 8-K with items 2.02 and 9.01 disclosing financial results.
- Jul 8LeadershipSEC
8-K filing (items 5.02,7.01,9.01) disclosing officer or director changes.